PL3638277T3 - Kompozycje i sposoby hamowania beta sekretazy - Google Patents

Kompozycje i sposoby hamowania beta sekretazy

Info

Publication number
PL3638277T3
PL3638277T3 PL18816475.0T PL18816475T PL3638277T3 PL 3638277 T3 PL3638277 T3 PL 3638277T3 PL 18816475 T PL18816475 T PL 18816475T PL 3638277 T3 PL3638277 T3 PL 3638277T3
Authority
PL
Poland
Prior art keywords
compositions
methods
beta secretase
secretase inhibition
inhibition
Prior art date
Application number
PL18816475.0T
Other languages
English (en)
Inventor
Muhammed Majeed
Kalyanam Nagabhushanam
Original Assignee
Sami Labs Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sami Labs Limited filed Critical Sami Labs Limited
Publication of PL3638277T3 publication Critical patent/PL3638277T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Confectionery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL18816475.0T 2017-06-15 2018-06-14 Kompozycje i sposoby hamowania beta sekretazy PL3638277T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762520141P 2017-06-15 2017-06-15
PCT/US2018/037454 WO2018232063A1 (en) 2017-06-15 2018-06-14 Compositions and methods for beta secretase inhibition

Publications (1)

Publication Number Publication Date
PL3638277T3 true PL3638277T3 (pl) 2025-03-10

Family

ID=64655980

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18816475.0T PL3638277T3 (pl) 2017-06-15 2018-06-14 Kompozycje i sposoby hamowania beta sekretazy
PL18817403.1T PL3638278T3 (pl) 2017-06-15 2018-06-15 Kompozycje neuroprotekcyjne i ich zastosowanie

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18817403.1T PL3638278T3 (pl) 2017-06-15 2018-06-15 Kompozycje neuroprotekcyjne i ich zastosowanie

Country Status (9)

Country Link
US (2) US11458117B2 (pl)
EP (2) EP3638277B1 (pl)
JP (2) JP7209645B2 (pl)
KR (2) KR20190134809A (pl)
CA (2) CA3063751C (pl)
ES (1) ES3005508T3 (pl)
FI (1) FI3638277T3 (pl)
PL (2) PL3638277T3 (pl)
WO (2) WO2018232063A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3638277T3 (pl) * 2017-06-15 2025-03-10 Sami Labs Limited Kompozycje i sposoby hamowania beta sekretazy
US12465585B2 (en) * 2018-06-15 2025-11-11 Sami-Sabinsa Group Limited Compositions for the management of seizure induced neurotoxicity
CN110115712A (zh) * 2019-07-04 2019-08-13 兰州大学 一种同时激活氧化磷酸化通路和抑制糖酵解途径的激活剂及其应用
EP4021397A4 (en) * 2019-08-26 2023-09-27 Sami-Sabinsa Group Limited HERBAL ACTIVE INGREDIENTS AND THEIR EFFECT AGAINST POLLUTION
CN114246879B (zh) * 2021-12-30 2023-10-27 沈阳兴齐眼药股份有限公司 木蝴蝶苷b在制备用于预防、控制和/或治疗眼部疾病药物中的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945518B2 (en) * 2002-04-30 2015-02-03 Unigen, Inc. Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions
CA2703698C (en) * 2002-04-30 2016-11-22 Unigen Pharmaceuticals, Inc. Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
US8034387B2 (en) * 2002-04-30 2011-10-11 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
NZ545565A (en) * 2003-09-02 2009-06-26 Unigen Pharmaceuticals Inc Formulation of a mixture of Free-B-Ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
KR20080091436A (ko) * 2006-01-09 2008-10-13 카운실 오브 사이언티픽 엔드 인더스트리얼 리서치 위장관 독성, 관련 증상 및 궤양 치료용 천연물질
EP1986670B1 (en) * 2006-02-21 2017-06-28 Council of Scientific and Industrial Research Intestinal alpha-glucosidase inhibitors and a process for the isolation and use thereof
US20100029654A1 (en) * 2006-03-23 2010-02-04 Mount Sinai School Of Medicine Cardiovascular compositions and use of the same for the treatment of alzheimer's disease
KR20080008929A (ko) * 2006-11-20 2008-01-24 대한민국(관리부서 식품의약품 안전청장) 오록실린 a를 함유하는 인지 기능 장애 관련 질환의 예방및 개선용 건강기능식품
EP2890391A4 (en) * 2012-08-29 2016-03-09 Mannkind Corp METHOD AND COMPOSITION FOR TREATING HYPERGLYCEMIA
CA3043168C (en) * 2016-11-11 2021-05-18 Sami Labs Limited Composition containing oroxylin a and method of extraction thereof
PL3638277T3 (pl) * 2017-06-15 2025-03-10 Sami Labs Limited Kompozycje i sposoby hamowania beta sekretazy

Also Published As

Publication number Publication date
JP7209645B2 (ja) 2023-01-20
US20180360800A1 (en) 2018-12-20
JP2020523372A (ja) 2020-08-06
EP3638277A4 (en) 2021-03-17
CA3063757A1 (en) 2018-12-20
JP6796217B2 (ja) 2020-12-02
US11458117B2 (en) 2022-10-04
US10894029B2 (en) 2021-01-19
CA3063751A1 (en) 2018-12-20
EP3638277B1 (en) 2024-10-09
CA3063751C (en) 2023-01-03
PL3638278T3 (pl) 2022-10-03
EP3638278A4 (en) 2021-03-17
KR20190131589A (ko) 2019-11-26
WO2018232063A1 (en) 2018-12-20
US20180360801A1 (en) 2018-12-20
EP3638278B1 (en) 2022-05-11
ES3005508T3 (en) 2025-03-14
FI3638277T3 (fi) 2025-01-10
KR20190134809A (ko) 2019-12-04
EP3638277A1 (en) 2020-04-22
WO2018232224A1 (en) 2018-12-20
EP3638278A1 (en) 2020-04-22
JP2020523342A (ja) 2020-08-06
CA3063757C (en) 2023-08-01

Similar Documents

Publication Publication Date Title
IL277079A (en) Cartirin preparations and methods of use
IL280134A (en) Anti-CD112R preparations and methods
IL282225B1 (en) Immunotherapy preparations and methods
GB201718801D0 (en) Compositions and methods for inhibiting factor D
SG10202109655VA (en) Compositions and methods for immunooncology
GB201807325D0 (en) Compositions and methods
LT3189074T (lt) Kompozicijos ir būdai skirti uždegimo gydymui ir prevencijai
SG11202101777VA (en) Methods and compositions for the modification of plants
IL274524A (en) Preparations and methods for aquaculture
IL271256A (en) Preparations and methods for the treatment of teopathy
SG11202104448WA (en) Compositions and methods
IL282824A (en) Preparations and methods for treating transient biofilms
PT3801534T (pt) Tratamento de fenilcetonúria com sepiapterina
ZA202004532B (en) Compositions for the management of hyperglycemia and related conditions
ZA202001320B (en) Compounds and compositions for ire1 inhibition
SG11202003261PA (en) Sanitizing compositions and methods for making and using same
SG10201913497XA (en) Biopharmaceutical compositions and related methods
GB201817444D0 (en) Methods and compositions
ZA202004533B (en) Skin-brightening compositions and methods
IL281875A (en) Composition of suspension and solution
IL277058A (en) Compositions and methods for inhibiting expression of GYS2
AU2018301500A1 (en) Methods and compositions for treating inflammation
IL258222A (en) Compositions and methods for inhibiting beta-lactamase
GB201819987D0 (en) Methods and compositions
PL3568203T3 (pl) Związki i kompozycje